A plethora of personnel changes is taking place in the pharmaceutical industry around Asia as a new year arrives.

As investment pours into Chinese biologic startups, a talent hunt is on, underscored by two announcements of new senior appointments at CANbridge and Zai Lab. Meanwhile, clinical research organization ICON has appointed new leadership for Asia and Meiji Seika is strengthening its CNS business.